4,430 Incyte Corporation $INCY Shares Purchased by Profund Advisors LLC

Profund Advisors LLC lifted its stake in Incyte Corporation (NASDAQ:INCY) by 30.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,152 shares of the biopharmaceutical company’s stock after purchasing an additional 4,430 shares during the period. Profund Advisors LLC’s holdings in Incyte were worth $2,324,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Vise Technologies Inc. grew its holdings in Incyte by 13.6% during the third quarter. Vise Technologies Inc. now owns 8,132 shares of the biopharmaceutical company’s stock valued at $987,000 after purchasing an additional 976 shares during the period. Grandfield & Dodd LLC increased its position in Incyte by 0.8% in the third quarter. Grandfield & Dodd LLC now owns 20,980 shares of the biopharmaceutical company’s stock worth $2,546,000 after buying an additional 158 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al raised its stake in shares of Incyte by 54.8% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 844,389 shares of the biopharmaceutical company’s stock worth $102,467,000 after buying an additional 299,014 shares during the period. Parcion Private Wealth LLC raised its stake in shares of Incyte by 3.7% in the third quarter. Parcion Private Wealth LLC now owns 5,839 shares of the biopharmaceutical company’s stock worth $709,000 after buying an additional 206 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Incyte by 16.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 36,984 shares of the biopharmaceutical company’s stock valued at $4,556,000 after buying an additional 5,189 shares in the last quarter. 96.97% of the stock is owned by institutional investors.

Incyte Price Performance

NASDAQ INCY opened at $120.39 on Monday. The firm has a market cap of $24.54 billion, a price-to-earnings ratio of 64.04, a price-to-earnings-growth ratio of 4.99 and a beta of 0.78. The business has a 50-day moving average price of $120.49 and a 200-day moving average price of $108.14. Incyte Corporation has a twelve month low of $89.25 and a twelve month high of $132.60.

Incyte (NASDAQ:INCY) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.93) by $0.33. The company had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.46 billion. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The firm’s quarterly revenue was up 14.0% on a year-over-year basis. During the same quarter last year, the company earned $2.26 EPS. Research analysts expect that Incyte Corporation will post 1.97 EPS for the current fiscal year.

More Incyte News

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Incyte reported third-quarter revenue of $1.56 billion, up 14% year over year and above the $1.46 billion analyst estimate. Adjusted loss of $3.60 per share was narrower than expected, helping support the stock. INCY Q3 Loss Narrower Than Expected, Sales Beat, FY’26 View Raised
• Positive Sentiment: The company raised 2026 total net-sales guidance to $5.21 billion-$5.30 billion, from $5.13 billion-$5.26 billion previously. Opzelura guidance was also increased to $1.10 billion-$1.12 billion, reflecting continued demand. Incyte signals 2026 net sales outlook as Opzelura guidance rises
• Positive Sentiment: Product trends were favorable: Opzelura sales rose 36% to $255 million, while hematology and oncology portfolio sales increased 38% to $235 million. Jakafi and Jakafi XR sales grew 4% to $827 million. Incyte Reports $1.56 Billion Third-Quarter Revenue and Raises 2026 Sales Guidance
• Positive Sentiment: Barclays raised its price target from $139 to $143 and maintained an “overweight” rating, implying substantial upside and reinforcing the bullish reaction. Barclays Incyte analyst recommendation
• Neutral Sentiment: Wells Fargo lowered its target slightly to $127 and kept an “equal weight” rating, while RBC raised its target to $117 but retained a “sector perform” rating. The changes indicate limited conviction among some analysts. Wells Fargo Incyte analyst recommendation
• Negative Sentiment: Incyte posted a GAAP loss largely because of a $1.23 billion in-process research and development charge tied to the Vega Therapeutics acquisition. The unusual charge obscures underlying operating strength and may keep investors focused on acquisition execution. Incyte Posts Q3 Loss on Vega Acquisition Charge

Insiders Place Their Bets

In other Incyte news, insider Pablo Cagnoni sold 10,801 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $125.56, for a total transaction of $1,356,173.56. Following the completion of the sale, the insider directly owned 183,200 shares of the company’s stock, valued at $23,002,592. This trade represents a 5.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 16.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on INCY. Canaccord Genuity Group initiated coverage on Incyte in a research note on Thursday, August 20th. They set a “buy” rating and a $152.00 price objective for the company. Benchmark restated a “buy” rating on shares of Incyte in a research note on Tuesday, October 13th. Wells Fargo & Company lowered their price target on shares of Incyte from $128.00 to $127.00 and set an “equal weight” rating on the stock in a report on Friday. Mizuho upped their price target on shares of Incyte from $121.00 to $137.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Finally, Morgan Stanley began coverage on shares of Incyte in a research note on Tuesday, October 20th. They issued an “equal weight” rating and a $119.00 price objective for the company. Twelve analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Incyte has an average rating of “Hold” and a consensus price target of $132.90.

Incyte Profile

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.